Laura Joszt, MA

Cardiomyopathies currently have no cures, but many of these disorders are prime candidates for gene therapies.

Gene therapies are revolutionizing treatment for hemophilia A and sickle cell disease; however, they are saddled with hefty price tags and limited patient populations that are impacting uptake.

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.

Gene therapies have a lot of potential to improve health outcomes for patients with life-threatening diseases but face a number of barriers that restrict access.

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for patients with hereditary angioedema.

A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD) is associated with quality-of-life improvements.

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted results of two real-world evidence studies of Apretude as an HIV prevention medication.

George O. Waring, IV, M.D., discusses the latest technology improving eyesight for patients.

Chronic and acute graft-versus-host disease are managed differently, affect different organs, and impact patients in different ways.

Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.

Even people living with HIV who have undetectable viral loads experience elevated inflammation levels, explained Michelle Cespedes, M.D., M.S, of Mount Sinai Health System.

The regimen has shown promise in preventing graft-versus-host disease in patients who received a haploidentical stem cell transplant.

A study found omitting a course of antibiotic prophylaxis was non-inferior to the routinely administering antibiotics in patients undergoing allogeneic hematopoietic stem cell transplantation.

Three different doses of Niktimvo all had high rates of response among patients with recurrent or refractory graft-versus-host disease (GVHD).

The retrospective analysis found Black patients were more likely to develop severe graft versus host disease (GVHD) and have a higher risk of nonrelapse mortality than White patients after hematopoietic stem cell transplantation.

For patients with interstitial lung disease (ILD), a subsequent diagnosis of pulmonary hypertension substantially increases utilization of healthcare resources as well as costs.

The decision comes after the FDA Oncologic Drugs Advisory Committee provided a unanimous vote recommending approval. Carvykti is now available to treat patients after just one prior line of therapy.

The chimeric antigen receptor T-cell (CART-T) therapy is now approved to treat patients with multiple myeloma after two prior lines of therapy.

The report from the American Medical Association evaluates health insurer market share at the metropolitan statistical area level and national level.

A simulation study estimated the impact of biosimilar substitution on total cost of care and provider financial performance in the final performance period of the Oncology Care Model.

A subgroup analysis of real-world patient survey data found Black/African American patients with moderate to severe atopic dermatitis had improved disease control, symptoms and treatment satisfaction on Dupixent.

Results of a phase 3, 52-week study showed a higher dose of Dupixent (dupilumab) reduced disease severity and improved signs and symptoms.

Children with atopic dermatitis (AD) are more likely than children without AD to react to a patch test and should be referred to a specialist for evaluation.

Two posters presented at the European Respiratory Society International Congress found use of Dupixent improved lung function by 12 weeks with sustained responses.

Findings presented at the European Respiratory Society found that using Dupixent to treat acute exacerbations of chronic obstructive pulmonary disease (COPD) reduced duration of systemic corticosteroid days.

Patients with atopic dermatitis (AD) and caregivers of children with AD highlighted strategies that they felt would manage AD-related mental health burden.

A post hoc analysis of two phase 3 trials identified that as many as 95% of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) had type 2 inflammatory signatures depending on the definition of inflammation used.

In an interview with MHE, Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, talked about the latest geographic atrophy treatments, pegcetacoplan and avacincaptad pegol, from a coverage and healthcare resource utilization standpoint, as both will potentially be available for the chronic disease that previously had no treatments.

Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, chatted with MHE about the latest geographic atrophy treatments and shared key takeaways found from clinical trials examining them. Hahn presented on macular degeneration today at the American Society of Retina Specialists annual meeting in Seattle.

Patients with multiple sclerosis (MS) with a plant-rich diet had less symptom burden compared with patients with MS who had an elevated intake of red meat and processed meat.